HK Stock Market Move | INSILICO (03696) rises more than 6% against the market trend. The Phase III clinical conference of Rentosertib is held, verifying the AI research and development capabilities once again.

INSILICO (03696) rose more than 6% against the market trend, rising 6.65% to HK$35.92 as of the time of writing, with a turnover of HK$48.59 million. On the news front, recently, INSILICO held a meeting of researchers for the Phase III clinical trial of Rentosertib for the treatment of IPF. It is reported that Rentosertib (ISM001-055) is the company's fastest progressing pipeline and the world's first candidate drug discovered and designed entirely by generative AI, completing Phase IIa clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Southwest released a research report stating that the IPF market space is vast, and if ISM001-055 can be successfully marketed, it has the potential to be a disruptive therapy. With more pipeline assets entering clinical trials and external licensing, the company is expected to see continued value realization. The firm stated that as core assets progress in clinical trials, the company's AI research and development capabilities will be further validated.